Greg Sackuvich

1 month ago | medcentral.com | Marc E. Agronin |Ivan Oransky |Charles Piller |Greg Sackuvich

The oral NMDA receptor antagonist/sigma-1 receptor agonist AXS-05 significantly delayed and prevented Alzheimer’s disease agitation relapse compared with placebo, according to results of the ACCORD-2 trial presented at the 2025 American Academy of Neurology annual meeting held in San Diego this week. “These results support the use of AXS-05 as a safe and effective treatment for AD agitation,” said George Grossberg, MD, of Saint Louis University School of Medicine, St. Louis, MO.